NeurExo Sciences and Henry Ford Health System Present Preclinical Data on Exosomes at ISEV2019 Annual Meeting
FOR IMMEDIATE RELEASE (PDF DOWNLOAD) Exosomes demonstrate ability to enhance anti-tumor effect of platinum-based drugs and to ameliorate peripheral neuropathy ATLANTA and DETROIT, April 26, 2019 – NeurExo Sciences, LLC (NXS), a biotechnology company...
read moreNeurExo Sciences and Henry Ford Health System Announce Upcoming Presentations on Exosomes at ISEV2019 Annual Meeting
FOR IMMEDIATE RELEASE ATLANTA and DETROIT, April 22, 2019 – NeurExo Sciences, LLC (NXS), a subsidiary of NeuroTrauma Sciences, LLC, and biotechnology company focused on the development of exosome therapies, and Henry Ford Health System (HFHS), a non-profit...
read moreNeurExo Sciences and Henry Ford Health System Announce Upcoming Presentations on Exosomes in Stroke at 45th International Stroke Conference February 6-8
Dr. Michael Chopp to Highlight Advances in Stroke at Exosome Teach-In Event in New York on February 12th ATLANTA, DETROIT and HONOLULU, January 31, 2019 – NeurExo Sciences, LLC (NXS), a biotechnology company focused on the development of exosome therapies,...
read moreNeurExo Sciences to Host Teach-in Featuring Michael Chopp, PhD and Pioneering Exosome Technology
Research indicates exosomes have therapeutic potential for improving recovery after stroke, traumatic brain injury ATLANTA and DETROIT, January 23, 2019 – NeurExo Sciences, LLC (NXS), a biopharmaceutical company and subsidiary of NeuroTrauma Sciences, LLC, will be...
read moreNeuroTrauma Sciences and Henry Ford Health System Announce Research and License Agreements to Develop Exosome Technology for Neurological Injury
Research indicates exosomes have therapeutic potential for improving recovery after stroke, traumatic brain injury ATLANTA and DETROIT, July 16, 2018 – NeuroTrauma Sciences, LLC (NTS), a biopharmaceutical company, and Henry Ford Health System, a...
read more